Frontiers in nephrology最新文献

筛选
英文 中文
Artificial intelligence for precision nephrology: current evidence to clinical translation and future prospects. 人工智能用于精确肾脏病学:临床转化的当前证据和未来前景。
IF 2.9
Frontiers in nephrology Pub Date : 2026-10-30 eCollection Date: 2026-01-01 DOI: 10.3389/fneph.2026.1950125
Moses Ishaku Madami, Chigozirim Samuel Amaoge, Ayu Wulandari, Xiaoshuang Zhou
{"title":"Artificial intelligence for precision nephrology: current evidence to clinical translation and future prospects.","authors":"Moses Ishaku Madami, Chigozirim Samuel Amaoge, Ayu Wulandari, Xiaoshuang Zhou","doi":"10.3389/fneph.2026.1950125","DOIUrl":"https://doi.org/10.3389/fneph.2026.1950125","url":null,"abstract":"<p><strong>Background and objectives: </strong>Artificial intelligence (AI) is increasingly being applied across nephrology, with potential applications spanning disease prediction, diagnosis, treatment optimisation, and clinical decision support. However, reported model performance varies substantially across clinical domains, and high predictive performance does not necessarily demonstrate clinical utility or readiness for deployment. This narrative review synthesizes current evidence on the applications of AI in nephrology and critically evaluates the methodological maturity, validation, interpretability, fairness, and translational readiness of AI systems across major nephrology domains.</p><p><strong>Methods: </strong>A structured literature search of PubMed was conducted using terms related to AI and nephrology, with the primary eligibility period restricted to studies published from 2020 to 2025. The search strategy incorporated artificial intelligence, machine learning, deep learning, neural networks, natural language processing, large language models, generative AI, computer vision, reinforcement learning, federated learning, and related terms, together with nephrology and kidney-disease terms. Title/abstract and full-text screening were performed independently by the first and second authors, with disagreements resolved by the third author. Two foundational pre-2020 studies identified through citation chaining were retained because of their importance to the subsequent development of AI applications in nephrology. Evidence was synthesized qualitatively according to study design, validation, predictive performance, interpretability, fairness, prospective evaluation, and translational readiness.</p><p><strong>Results: </strong>AI applications were identified across acute kidney injury, chronic kidney disease, nephropathology, kidney transplantation, haemodialysis, peritoneal dialysis, large language models, reinforcement learning, and federated learning. Across these domains, many models demonstrated promising discrimination, but evidence maturity varied considerably. External validation was present for some applications, whereas prospective evaluation and evidence of clinical utility remained limited. The literature also highlighted challenges related to calibration, generalizability, interpretability, algorithmic fairness, data governance, and integration into clinical workflows. Large language models and federated learning represent emerging areas, but nephrology-specific evidence remains comparatively limited.</p><p><strong>Conclusions: </strong>AI has substantial potential to support precision nephrology, but technical performance should not be equated with clinical effectiveness or deployment readiness. Future research should prioritize external and prospective validation, assessment of clinical utility and patient outcomes, transparent reporting, fairness, regulatory oversight, and effective human-AI integration.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"6 ","pages":"1950125"},"PeriodicalIF":2.9,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13760361/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149413611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Case Report: Uromodulin-associated autosomal dominant tubulointerstitial kidney disease: case analysis and literature review. 病例报告:尿调素相关常染色体显性小管间质肾病:病例分析和文献复习。
IF 2.9
Frontiers in nephrology Pub Date : 2026-10-29 eCollection Date: 2026-01-01 DOI: 10.3389/fneph.2026.1931661
Linlin Zheng, Hui Gao, Xiangkai Zheng, Xing Zhang, Xiaona Wei
{"title":"Case Report: Uromodulin-associated autosomal dominant tubulointerstitial kidney disease: case analysis and literature review.","authors":"Linlin Zheng, Hui Gao, Xiangkai Zheng, Xing Zhang, Xiaona Wei","doi":"10.3389/fneph.2026.1931661","DOIUrl":"https://doi.org/10.3389/fneph.2026.1931661","url":null,"abstract":"<p><p>Autosomal dominant tubulointerstitial kidney disease caused by <i>UMOD</i> variants (ADTKD-UMOD) is a rare hereditary disorder characterized by early-onset hyperuricemia, gout, and progressive kidney dysfunction. Diagnosis is established by genetic testing. We report the case of a 25-year-old man who presented with elevated serum creatinine (Scr) and uric acid (UA) levels. His father and elder sister had chronic kidney disease of unknown etiology, suggesting an autosomal dominant inheritance pattern. A comprehensive evaluation excluded secondary causes of hyperuricemia and kidney dysfunction. Genetic testing identified a novel heterozygous missense variant, <i>UMOD</i> (NM_003361.4): c.274T>A (p.Cys92Ser), in exon 3 of the gene. The same variant was also detected in affected relatives. In silico analyses predicted a deleterious effect, and the variant was classified as likely pathogenic according to the ACMG/AMP criteria (PM5_Moderate, PP3_Moderate, PM2_Supporting). During longitudinal follow-up with febuxostat treatment, serum urate levels decreased, while progressive deterioration of renal function was observed during the observational period. By analogy to well-characterized pathogenic cysteine-altering <i>UMOD</i> variants, we hypothesize that p.Cys92Ser may promote uromodulin misfolding and endoplasmic reticulum retention and thereby contribute to kidney injury; this mechanistic inference remains to be verified by direct functional experiments for this novel variant. This report expands the mutational spectrum of ADTKD-UMOD and underscores the importance of early genetic testing in at-risk families, as well as standardized long-term follow-up and management for this progressive disorder.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"6 ","pages":"1931661"},"PeriodicalIF":2.9,"publicationDate":"2026-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13754732/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149413612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exercise training in kidney transplant recipients (EXTRA Trial): protocol for a randomized controlled trial. 肾移植受者的运动训练(EXTRA试验):一项随机对照试验方案。
IF 2.9
Frontiers in nephrology Pub Date : 2026-10-26 eCollection Date: 2026-01-01 DOI: 10.3389/fneph.2026.1972911
Rafael L Santos, Thiago S Rosa, Samara Sezana-Costa, Suyane R Lisboa, Marco Aurélio M Estivalet, Carlos Ernesto Santos Ferreira, Gislane Ferreira de Melo, Lysleine Alves de Deus, José Adeirton, Michel K Souza, Anderson S Haro, Fernando Costa, Mariana Campos A Mattos, José R B Neto, Carmen Tzanno-Martins, Daniel M Mendes, Guilherme T Ribas, Geraldo R R Freitas, Mauricio Castro-Sepulveda, Adriana Bañares-Cruz, Thiago J Borges, Leonardo V Riella, Rodrigo P Neves, Hugo L Correa
{"title":"Exercise training in kidney transplant recipients (EXTRA Trial): protocol for a randomized controlled trial.","authors":"Rafael L Santos, Thiago S Rosa, Samara Sezana-Costa, Suyane R Lisboa, Marco Aurélio M Estivalet, Carlos Ernesto Santos Ferreira, Gislane Ferreira de Melo, Lysleine Alves de Deus, José Adeirton, Michel K Souza, Anderson S Haro, Fernando Costa, Mariana Campos A Mattos, José R B Neto, Carmen Tzanno-Martins, Daniel M Mendes, Guilherme T Ribas, Geraldo R R Freitas, Mauricio Castro-Sepulveda, Adriana Bañares-Cruz, Thiago J Borges, Leonardo V Riella, Rodrigo P Neves, Hugo L Correa","doi":"10.3389/fneph.2026.1972911","DOIUrl":"10.3389/fneph.2026.1972911","url":null,"abstract":"<p><p>Kidney transplantation improves survival and quality of life compared with long-term dialysis, yet many kidney transplant recipients remain characterized by reduced physiological reserve, cardiometabolic vulnerability, and ongoing graft-related risk. Structured exercise is a promising non-pharmacological strategy after transplantation, but its potential immunometabolic and immunomodulatory effects and their relationship with longer-term graft-related trajectories remain insufficiently characterized. The EXercise Training in Kidney TRAnsplant Recipients Trial (EXTRA Trial) is a randomized, assessor-blinded, parallel-group controlled trial that enrolled adult kidney transplant recipients approximately 6 months after transplantation. Participants are allocated 1:1 to usual post-transplant care or a supervised, progressive, combined aerobic and resistance exercise program consisting of a 2-week familiarization period followed by 24 weeks of training. The primary outcomes are the between-group differences in change in peak oxygen uptake (VO<sub>2</sub>peak) and handgrip strength from baseline to the end of the randomized intervention. VO<sub>2</sub>peak serves as the principal cardiorespiratory outcome and the basis for the sample-size calculation. Major secondary outcomes include patient-reported physical functioning, habitual physical activity, health-related quality of life, body composition, renal function, blood pressure, and metabolic markers. Exploratory outcomes include rejection-free survival, graft survival, circulating inflammatory cytokines (TNF-α, IL-6, and IL-2), soluble PD-1 and PD-L1, and longer-term trajectories assessed through 24 months after transplantation. The protocol follows SPIRIT 2025 recommendations and integrates exercise physiology, transplant medicine, and immune-related phenotyping to examine whether exercise-induced improvements in physiological reserve are accompanied by measurable inflammatory, immune-checkpoint, and graft-related changes.</p><p><strong>Clinical trial registration: </strong>ClinicalTrials.gov, identifier NCT06216015.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"6 ","pages":"1972911"},"PeriodicalIF":2.9,"publicationDate":"2026-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13745256/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149382122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Modality, utilization and mortality in pediatric ESKD: a registry-based study. 儿童ESKD的治疗方式、使用和死亡率:一项基于登记的研究。
IF 2.9
Frontiers in nephrology Pub Date : 2026-10-26 eCollection Date: 2026-01-01 DOI: 10.3389/fneph.2026.1930091
Subodh J Saggi, Anil Mongia, Angelika C Gruessner, Mary Mallappallil, Moro Salifu
{"title":"Modality, utilization and mortality in pediatric ESKD: a registry-based study.","authors":"Subodh J Saggi, Anil Mongia, Angelika C Gruessner, Mary Mallappallil, Moro Salifu","doi":"10.3389/fneph.2026.1930091","DOIUrl":"10.3389/fneph.2026.1930091","url":null,"abstract":"<p><strong>Introduction: </strong>Pediatric end-stage renal disease (ESKD) is rare but clinically complex. This study evaluated modality utilization, transplant access, and mortality among pediatric ESKD patients in the IPRO Network registry.</p><p><strong>Methods: </strong>We performed a retrospective registry-based analysis of 1,628 pediatric ESKD patients from four U.S. regions between 2018 and 2024. Descriptive statistics summarized patient characteristics and treatment patterns. Competing risk models were used to assess time to modality transition, transplant listing, transplantation, and survival.</p><p><strong>Results: </strong>Pediatric patients represented 0.65% of all ESKD cases in the network. Peritoneal dialysis (PD) was the most common initial modality in children aged 0-2 years (72%), compared with 24% in those aged 15-17 years. Overall, 46% started hemodialysis (HD), 31% PD, and 23% were preemptively listed for transplantation. Transitions from HD to PD were uncommon. Transplant listing occurred in 63% of patients by 1 year and 81% by 3 years; transplantation occurred in 22% and 53%, respectively. One-, two-, and three-year mortality rates were 3.4%, 5.4%, and 6.6%, with the highest mortality rate in children aged 0-2 years (10% at 3 years).</p><p><strong>Discussion: </strong>PD is the preferred initial modality in very young children, while older children more often start hemodialysis. Overall survival and transplant access were favorable, but infants and toddlers remained the most vulnerable subgroup.</p><p><strong>Conclusion: </strong>Pediatric ESKD accounts for a small but distinct share of the ESKD population. Early transplant access and good short-term survival were observed, but outcomes remain poorest in the youngest children.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"6 ","pages":"1930091"},"PeriodicalIF":2.9,"publicationDate":"2026-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13745325/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149382124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Glycaemic screening before kidney transplantation should include an oral glucose tolerance test. 肾移植前的血糖筛查应包括口服葡萄糖耐量试验。
IF 2.9
Frontiers in nephrology Pub Date : 2026-10-23 eCollection Date: 2026-01-01 DOI: 10.3389/fneph.2026.1849545
Espen Nordheim, Trond Geir Jenssen, Jørn Petter Lindahl, Kåre Inge Birkeland, Karsten Midtvedt, Kristian Heldal, Morten Hagness, Markus Hovd, Anders Åsberg
{"title":"Glycaemic screening before kidney transplantation should include an oral glucose tolerance test.","authors":"Espen Nordheim, Trond Geir Jenssen, Jørn Petter Lindahl, Kåre Inge Birkeland, Karsten Midtvedt, Kristian Heldal, Morten Hagness, Markus Hovd, Anders Åsberg","doi":"10.3389/fneph.2026.1849545","DOIUrl":"10.3389/fneph.2026.1849545","url":null,"abstract":"","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"6 ","pages":"1849545"},"PeriodicalIF":2.9,"publicationDate":"2026-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13746163/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149382123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Calcineurin inhibitors treatment in kidney transplant recipients is frequently associated with hyperkalemia, acidosis and hypertension but not with increased expression or phosphorylation of the sodium chloride cotransporter. 肾移植受者钙调磷酸酶抑制剂治疗通常与高钾血症、酸中毒和高血压有关,但与氯化钠共转运蛋白表达或磷酸化增加无关。
IF 2.9
Frontiers in nephrology Pub Date : 2026-10-22 eCollection Date: 2026-01-01 DOI: 10.3389/fneph.2026.1917605
Ludovic Di Ascia, Jennifer Baraka-Vidot, Cyril Ferdynus, Jean-Paul Duong, Céline Bairras Martin, Pierre Merville, Lionel Couzi, Dominique Eladari, Régine Chambrey
{"title":"Calcineurin inhibitors treatment in kidney transplant recipients is frequently associated with hyperkalemia, acidosis and hypertension but not with increased expression or phosphorylation of the sodium chloride cotransporter.","authors":"Ludovic Di Ascia, Jennifer Baraka-Vidot, Cyril Ferdynus, Jean-Paul Duong, Céline Bairras Martin, Pierre Merville, Lionel Couzi, Dominique Eladari, Régine Chambrey","doi":"10.3389/fneph.2026.1917605","DOIUrl":"10.3389/fneph.2026.1917605","url":null,"abstract":"<p><strong>Background and hypothesis: </strong>Calcineurin inhibitors (CNIs), widely used after kidney transplantation, may alter signaling pathways regulating the NaCl cotransporter (NCC), potentially causing an acquired form of pseudo-hypoaldosteronism type II (PHAII), characterized by hyperkalemia, metabolic acidosis, and hypertension.</p><p><strong>Methods: </strong>We assessed the prevalence of a PHAII-like phenotype in kidney transplant recipients (KTRs) receiving CNIs in two independent cohorts: a retrospective cohort (n = 172) and a prospective cohort (n = 58). In the prospective cohort, NCC and phosphorylated NCC (pNCC) abundance were measured in urinary extracellular vesicles (uEVs).</p><p><strong>Results: </strong>Approximately 25% of KTRs exhibited a PHAII-like phenotype in both cohorts. Contrary to expectations, NCC and pNCC expression in uEVs were lower in CNI-treated KTRs than in healthy volunteers. No differences in NCC or pNCC abundance were observed between KTRs with and without the phenotype. Similarly, kidney transplant biopsies from patients with the phenotype showed NCC and pNCC staining comparable to control biopsies from patients with minimal change disease.</p><p><strong>Conclusion: </strong>Although hyperkalemia, metabolic acidosis, and hypertension frequently coexist in CNI-treated KTRs, the absence of NCC upregulation does not support the hypothesis that chronic CNI therapy induces the characteristic molecular abnormalities of PHAII.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"6 ","pages":"1917605"},"PeriodicalIF":2.9,"publicationDate":"2026-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13735607/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149344936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Combination finerenone and empagliflozin for chronic kidney disease with type 2 diabetes: a target trial emulation. 芬尼酮联合恩格列净治疗慢性肾病合并2型糖尿病:目标试验模拟
IF 2.9
Frontiers in nephrology Pub Date : 2026-10-20 eCollection Date: 2026-01-01 DOI: 10.3389/fneph.2026.1930977
Lei Li, Dan Zhang, Manrong Xu, Shaohua Li, Yun Shen, Shengdi Lu
{"title":"Combination finerenone and empagliflozin for chronic kidney disease with type 2 diabetes: a target trial emulation.","authors":"Lei Li, Dan Zhang, Manrong Xu, Shaohua Li, Yun Shen, Shengdi Lu","doi":"10.3389/fneph.2026.1930977","DOIUrl":"10.3389/fneph.2026.1930977","url":null,"abstract":"<p><strong>Objective: </strong>This study aims to emulate the CONFIDENCE trial and compare combination finerenone plus empagliflozin with each monotherapy for albuminuria reduction in Chinese patients with chronic kidney disease (CKD) and type 2 diabetes (T2D).</p><p><strong>Design: </strong>This study employed modified target trial emulation. The primary contrast was the per-protocol effect, estimated by cloning, censoring, and inverse probability of censoring weighting, which is not susceptible to grace-period immortal time bias; a propensity-score-matched assignment analysis, the observational analogue of intention-to-treat, was secondary.</p><p><strong>Setting: </strong>Electronic health records from three Chinese tertiary (Grade A) hospitals, from January 2023 to September 2025, were utilized.</p><p><strong>Participants: </strong>A total of 2,895 adults (965 per strategy) with CKD and T2D met the CONFIDENCE eligibility criteria, selected by 1:1:1 propensity score matching from 3,822 eligible patients.</p><p><strong>Main outcome measures: </strong>Relative change in urine albumin-to-creatinine ratio (UACR) from baseline to day 180 was the main outcome measure (co-primary comparisons with Holm-Bonferroni correction).</p><p><strong>Results: </strong>At day 180, the median UACR reduction was 52.0% in the combination strategy, 32.1% with finerenone, and 28.9% with empagliflozin. In the per-protocol analysis the difference was -19.5 percentage points (95% confidence interval -20.5 to -18.5) versus finerenone and -22.8 (-23.8 to -21.8) versus empagliflozin. The secondary assignment analysis gave -19.6 (-20.5 to -18.7) and -22.9 (-23.8 to -22.0), respectively (both <i>P</i> < 0.001); this is not a true intention-to-treat effect and is supportive only. Hyperkalemia occurred in 12.7%, 12.8%, and 3.5%, respectively, acute kidney injury in 4.9%, 2.8%, and 2.3%, respectively, and symptomatic hypotension in 1.9%, 0.6%, and 0.4%, respectively. The findings were consistent across 10 sensitivity analyses and six subgroups.</p><p><strong>Conclusions: </strong>Combination finerenone and empagliflozin was associated with greater albuminuria reduction than either monotherapy, directionally consistent with CONFIDENCE. Because the emulated strategy permitted sequential initiation within 90 days whereas CONFIDENCE randomized simultaneous initiation, this is a modified emulation rather than a direct replication. Albuminuria is a surrogate endpoint and follow-up was 180 days, so hard kidney and cardiovascular outcomes remain unstudied. Despite loss to follow-up of 29.6% to 32.7%, the finding was robust in a tipping-point analysis. Hyperkalemia was frequent with finerenone, so biochemical monitoring remains necessary. Findings apply to comparable Chinese tertiary-care populations.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"6 ","pages":"1930977"},"PeriodicalIF":2.9,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13727606/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149328133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ultrasound-guided haemodynamic profiling in haemodialysis patients: a single-centre prospective observational study protocol. 超声引导血液透析患者血流动力学分析:一项单中心前瞻性观察研究方案。
IF 2.9
Frontiers in nephrology Pub Date : 2026-10-20 eCollection Date: 2026-01-01 DOI: 10.3389/fneph.2026.1939088
Samuel Larsen, Fabio Silvio Taccone, Alain Le Moine, Filippo Annoni, Thomas Baudoux
{"title":"Ultrasound-guided haemodynamic profiling in haemodialysis patients: a single-centre prospective observational study protocol.","authors":"Samuel Larsen, Fabio Silvio Taccone, Alain Le Moine, Filippo Annoni, Thomas Baudoux","doi":"10.3389/fneph.2026.1939088","DOIUrl":"10.3389/fneph.2026.1939088","url":null,"abstract":"<p><strong>Background: </strong>Intradialytic hypotension (IDH) and chronic fluid overload are common and clinically important complications of maintenance haemodialysis, yet routine volume assessment remains imprecise. Multi-organ point-of-care ultrasound may provide a structured bedside assessment of cardiac reserve, pulmonary congestion and venous congestion.</p><p><strong>Methods and analysis: </strong>This single-centre prospective observational cohort study will enrol approximately 60 adult patients receiving maintenance haemodialysis. Participants will undergo integrated ultrasound profiling immediately before and after dialysis at baseline and at 3, 6 and 9 months, with clinical outcomes followed for 12 months. The ultrasound protocol includes focused cardiac ultrasound, eight-zone lung ultrasound B-line quantification and a modified VEXUS assessment using inferior vena cava, hepatic vein and portal vein findings. Event-triggered intradialytic scans may also be performed for current IDH or suspected mismatch between the prescribed target weight and the best clinically tolerated weight. These examinations will not be pooled with scheduled assessments. A separate exploratory post-scan association analysis will include only scans completed while the patient is clinically stable, before the first same-session IDH and not in response to evolving current-session haemodynamic instability; the outcome is subsequent IDH before session end. Scans obtained during or after IDH or during evolving instability will be described only. The main descriptive objective is to characterise pre- and post-dialysis ultrasound-derived haemodynamic profiles and their within-session and longitudinal variability. The primary prespecified analysis for Objective 2 is an exploratory and non-confirmatory assessment of the within-patient association between pre-dialysis ultrasound parameters and same-session IDH using a scheduled-session case-crossover design. Secondary analyses include the separate event-triggered post-scan association analysis and an exploratory scheduled-session mixed-effects analysis. Event-triggered examinations will not contribute cases to the primary analysis. Exploratory objectives assess clinician-perceived usefulness and documented clinician-implemented prescription changes after delayed disclosure, without assessing clinical benefit.</p><p><strong>Ethics and dissemination: </strong>The study has received ethics approval and will be conducted after written informed consent. Results will be disseminated through peer-reviewed publications and scientific meetings.</p><p><strong>Study registration: </strong>https://www.isrctn.com/ISRCTN80571205, identifier ISRCTN80571205.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"6 ","pages":"1939088"},"PeriodicalIF":2.9,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13727544/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149328134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence and factors associated with physical function among patients undergoing maintenance hemodialysis in Buraydah, Saudi Arabia: a cross-sectional study. 沙特阿拉伯Buraydah维持性血液透析患者的患病率和与身体功能相关的因素:一项横断面研究。
IF 2.9
Frontiers in nephrology Pub Date : 2026-10-14 eCollection Date: 2026-01-01 DOI: 10.3389/fneph.2026.1935072
Shereen Ahmed A Qalawa, Wafaa Abdullah AlQassem, Kholoud Metab Alomeri, Khalid Saad Alhumidi Alharbi, Ahmed Ibrahim ALsallom, Fatma Mohamed Elmansy, Mohamed Goda Elbqry
{"title":"Prevalence and factors associated with physical function among patients undergoing maintenance hemodialysis in Buraydah, Saudi Arabia: a cross-sectional study.","authors":"Shereen Ahmed A Qalawa, Wafaa Abdullah AlQassem, Kholoud Metab Alomeri, Khalid Saad Alhumidi Alharbi, Ahmed Ibrahim ALsallom, Fatma Mohamed Elmansy, Mohamed Goda Elbqry","doi":"10.3389/fneph.2026.1935072","DOIUrl":"https://doi.org/10.3389/fneph.2026.1935072","url":null,"abstract":"<p><strong>Background: </strong>Physical function is a key indicator of health status and quality of life among patients undergoing maintenance hemodialysis. Functional impairment is common in this population owing to the combined effects of chronic kidney disease, treatment-related burden, and multiple comorbidities, resulting in reduced independence and poorer health outcomes. However, evidence regarding the prevalence and factors associated with impaired physical function among maintenance hemodialysis patients in Saudi Arabia remains limited.</p><p><strong>Objective: </strong>This study aimed to determine the prevalence of physical function impairment and examine the factors associated with physical function among patients undergoing maintenance hemodialysis in Buraydah, Saudi Arabia.</p><p><strong>Methods: </strong>A hospital-based cross-sectional study was conducted at the Dialysis Center of King Fahd Specialized Hospital, Buraydah, Saudi Arabia. A convenience sample of 110 adult patients undergoing maintenance hemodialysis was recruited. Data were collected using a structured, validated questionnaire assessing sociodemographic and clinical characteristics, physical function, activities of daily living, anthropometric measurements, and laboratory parameters. Descriptive statistics and Chi-square tests were used to examine the associations between variables.</p><p><strong>Results: </strong>Among the 110 participants, 73.6% demonstrated impaired physical function. Age was the only participant characteristic significantly associated with physical function (p = 0.002), whereas no significant associations were observed with sex, marital status, educational level, employment status, dialysis duration, dialysis frequency, family history of kidney disease, or comorbidities. Participants reported substantial limitations in instrumental activities of daily living, particularly cleaning floors, washing clothes, cooking, carrying objects, and engaging in physical exercise, while most remained independent in basic self-care activities.</p><p><strong>Conclusion: </strong>Impaired physical function is highly prevalent among patients undergoing maintenance hemodialysis, with older age being significantly associated with poorer physical function. Routine assessment of physical function should be incorporated into dialysis care to facilitate the early identification of at-risk patients and support individualized interventions aimed at maintaining functional independence and improving quality of life.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"6 ","pages":"1935072"},"PeriodicalIF":2.9,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13713443/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149301795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Case Report: Monotypic IgG1-λ fibrillary glomerulonephritis associated with rheumatoid arthritis. 病例报告:单型IgG1-λ原纤维性肾小球肾炎与类风湿关节炎相关。
IF 2.9
Frontiers in nephrology Pub Date : 2026-10-13 eCollection Date: 2026-01-01 DOI: 10.3389/fneph.2026.1932311
Adam Nedoroscik, Jana Moravcova, Lenka Manakova, Oskar Zakiyanov, Romana Rysava, Vladimir Tesar, Marek Kollar
{"title":"Case Report: Monotypic IgG1-λ fibrillary glomerulonephritis associated with rheumatoid arthritis.","authors":"Adam Nedoroscik, Jana Moravcova, Lenka Manakova, Oskar Zakiyanov, Romana Rysava, Vladimir Tesar, Marek Kollar","doi":"10.3389/fneph.2026.1932311","DOIUrl":"https://doi.org/10.3389/fneph.2026.1932311","url":null,"abstract":"<p><strong>Background: </strong>Fibrillary glomerulonephritis (FGN) is a rare glomerular disease characterized by non-amyloid fibrillary deposits and is identified in fewer than 1% of native kidney biopsies. Most cases demonstrate polytypic immunoglobulin G deposition, whereas confirmed monotypic FGN is exceptionally uncommon and may raise concern for an underlying monoclonal gammopathy.</p><p><strong>Case presentation: </strong>A 72-year-old woman with rheumatoid arthritis presented with nephrotic-range proteinuria (4.6 g/24 h), microscopic hematuria, hypoalbuminemia, lower-extremity edema, and mildly impaired kidney function. Kidney biopsy demonstrated mesangial expansion and glomerular deposits staining for IgG, C3, and lambda light chain. The deposits were Congo red negative and showed strong, diffuse glomerular DNAJB9 positivity. Electron microscopy revealed randomly oriented, non-branching fibrils measuring approximately 20 nm, accompanied by podocyte foot-process effacement. Isolated IgG1 staining and lambda restriction, confirmed by immunofluorescence performed on pronase-digested paraffin-embedded tissue, supported a true monotypic IgG1-lambda phenotype. Serum immunofixation and serum free light-chain testing did not demonstrate a monoclonal protein, and no underlying hematological malignancy, other malignancy, or infection was identified. The patient received rituximab. At 14 months, proteinuria had decreased to approximately 1.0 g/24 h and serum albumin had increased from 30 to 38 g/L.</p><p><strong>Conclusion: </strong>Confirmed monotypic FGN is exceptionally rare and requires integration of routine immunofluorescence, IgG-subclass assessment, paraffin-embedded immunofluorescence, DNAJB9 immunohistochemistry, and electron microscopy. Light-chain restriction alone is insufficient to establish a truly monotypic process, and monotypic deposits warrant careful evaluation for an underlying clonal disorder. This case documents DNAJB9-positive monotypic IgG1-lambda FGN occurring in the setting of rheumatoid arthritis without demonstrable monoclonal gammopathy.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"6 ","pages":"1932311"},"PeriodicalIF":2.9,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13711040/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149290504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书